An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum

NCT02315417 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Pyoderma Gangrenosum

Interventions

DRUG: gevokizumab
DRUG: Placebo
DRUG: gevokizumab open-label

Sponsor

XOMA (US) LLC